.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Synaptic vesicle endocytosis is a fundamental process that sustains high-frequency neurotransmission by recycling vesicles at the synapse. While researchers have long recognized FCHO1 as an initiator of clathrin-mediated endocytosis, its specific synaptic role was previously unclear. A recent study published in Molecular Brain reveals that FCHO1 functions as a demand-sensitive scaffold. Notably, it scales its activity based on the intensity of neuronal stimulation.
The researchers utilized shRNA-mediated knockdown and live imaging to monitor vesicle retrieval kinetics. They found that depletion of FCHO1 significantly slows down the endocytic process across various stimulation paradigms. Specifically, the study highlights how the protein requires different structural domains at different activity levels. Furthermore, the F-BAR domain manages vesicle retrieval during low stimulation. However, the mu-homology domain (μ-HD) becomes vital as the endocytic load increases.
As neuronal activity escalates, the demand for rapid vesicle recycling grows. Consequently, FCHO1 adapts its structural contributions to meet these physiological needs. These findings suggest that multidomain proteins provide a flexible mechanism for maintaining synaptic efficiency. Therefore, understanding these molecular pathways could offer new insights into neurological conditions where synaptic recycling fails. Ultimately, this research establishes FCHO1 as a critical regulator of synaptic health.
FCHO1 acts as a regulator that fine-tunes the speed of synaptic vesicle endocytosis. It ensures that the rate of vesicle recycling matches the intensity of neuronal firing to prevent the depletion of the vesicle pool.
The F-BAR domain handles basic recycling needs under low activity. In contrast, the mu-homology domain is essential for handling the increased workload during high-frequency stimulation, making the protein a demand-sensitive scaffold.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Lee HJ et al. FCHO1 fine-tunes synaptic vesicle endocytosis in an activity-dependent manner. Mol Brain. 2026 Apr 06. doi: 10.1186/s13041-026-01295-1. PMID: 41943152.
Henne WM et al. FCHo proteins are nucleators of clathrin-mediated endocytosis. Science. 2010;328(5983):1281-1284.
Milosevic I. Synaptic Vesicle Endocytosis. Cold Spring Harb Perspect Biol. 2018;10(12):a033357.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Research identifies FCHO1 as a demand-sensitive scaffold that regulates synaptic vesicle endocytosis based on neuronal activity intensity....
5 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
